James Priour Biography and Net Worth

Insider of Zymeworks

Global biopharma and biotech business leader with drug development, portfolio strategy, commercialization, strategic partnership and CEO experience in both large and small entrepreneurial organizations. Worked in US, Europe (Western and Eastern) and Asia Pacific. Driver of growth and value creation.

What is James Priour's net worth?: The estimated net worth of James Priour is at least $69.78 thousand as of April 13th, 2021. Mr. Priour owns 2,953 shares of Zymeworks stock worth more than $69,779 as of February 24th. This net worth estimate does not reflect any other investments that Mr. Priour may own. Learn More about James Priour's net worth.
How do I contact James Priour?: The corporate mailing address for Mr. Priour and other Zymeworks executives is 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on James Priour's contact information.
Has James Priour been buying or selling shares of Zymeworks?: James Priour has not been actively trading shares of Zymeworks over the course of the past ninety days. Most recently, James Priour sold 950 shares of the business's stock in a transaction on Tuesday, April 13th. The shares were sold at an average price of $27.93, for a transaction totalling $26,533.50. Following the completion of the sale, the insider now directly owns 2,953 shares of the company's stock, valued at $82,477.29. Learn More on James Priour's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Kenneth Galbraith (Chair & CEO), Mark Hollywood (COO), Neil Josephson (Insider), Neil Klompas (CFO), Paul Moore (Chief Scientific Officer), Kathryn O'Driscoll (Insider), James Priour (Insider), Jeffrey Smith (Executive Vice President and Chief Medical Officer), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last year, Zymeworks insiders bought shares 13 times. They purchased a total of 1,405,768 shares worth more than $16,773,032.28. During the last year, insiders at the sold shares 8 times. They sold a total of 187,933 shares worth more than $4,673,716.04. The most recent insider tranaction occured on January, 12th when CEO Kenneth Galbraith sold 30,424 shares worth more than $689,712.08. Insiders at Zymeworks own 33.5% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 1/12/2026.

James Priour Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/13/2021	Sell	950	$27.93	$26,533.50	2,953

James Priour Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Today's Range

Now: $23.63

$22.80

$23.68

50 Day Range

MA: $24.19

$22.02

$27.62

2 Week Range

Now: $23.63

$9.03

$28.49

Volume

445,321 shs

Average Volume

777,076 shs

Market Capitalization

$1.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25